Alopecia and Hair Damage Induced by Oncological Therapy

Česká verzia

Authors: Hana Jedličková ¹; Samuel Vokurka ²; Radovan Vojtíšek ²; Anna Malečková ³
Authors place of work: Dermatovenerologické oddělení, FN Brno ¹; Onkologická a radioterapeutická klinika LF UK a FN Plzeň ²; Biomedicínské centrum, Ústav histologie a embryologie, LF UK v Plzni ³
Published in the journal: Klin Onkol 2019; 32(5): 353-359
Category: Přehled
doi: https://doi.org/10.14735/amko2019353

Summary

Damage and loss of hair (alopecia) is a predictable adverse event of oncological therapy. It can be caused by chemotherapy, radiotherapy, or targeted and hormonal therapy. From the point of view of patients with malignant disease, hair loss is one of the most feared side effects and adversely affects their mental health. Hair loss can be diffuse, complete, partial, or regional. Worsening of hair quality, cutaneous inflammation, and scarring can also occur. Eyelashes, eyebrows, and body hair can also be lost. Alopecia is mostly reversible, but permanent damage can occur depending on the type, overall length, and dose of oncological treatment and other factors. The risk of alopecia is high with high-dose docetaxel, doxorubicin, and cyclophosphamide, but low with platinum chemotherapy, melphalan, and capecitabin. Targeted therapy and immunotherapy can cause immune-mediated alopecia such as alopecia areata and scarring alopecia as well as paradoxically hypertrichosis and trichomegaly. Physical and pharmacological approaches can be used to prevent and treat alopecia; however, their effectiveness and availability are limited. Modern radiotherapy scalp-sparing methods minimize hair loss. Good results have been obtained with scalp cooling, which reduces the toxic effects of cytostatic agents on hair follicles during short infusion regimens. Several systems cool the scalp to less than 22°C. Minoxidil accelerates hair regrowth and is used as a topical therapy. Psychological support and provision of cosmetically acceptable head coverings are also very important.

Keywords:

radiotherapy – side effects – Quality of life – alopecia – Hormonal therapy – hirsutism

Zdroje

1. Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med 1979; 301 (26): 1427–1429. doi: 10.1056/NEJM197912273012605.

2. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of health and human services, National Institutes of Health, National Cancer Institute, 2017. [online]. Available from: https: //ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

3. World Health Organization. (1979). WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization. [online]. Available from: www.who.int/iris/handle/10665/37200.

4. Freites-Martinez A, Shapiro J, Goldfarb S et al. CME Part 1: Hair disorders in patients with cancer. J Am Acad Dermatol 2019; 80 (5): 1179–1196. doi: 10.1016 /j.jaad.2018.03.055.

5. Breed WP, Van den Hurk CJ, Peerbooms M. Presentation, impact and prevention of chemotherapy-induced hair loss: scalp cooling potentials and limitations. Expert Rev Dermatol 2011; 6 (1): 109–125. doi: 10.1586/edm.10.76.

6. Adya KA, Inamadar AC, Palit A et al. Light microscopy of the hair: a simple tool to “untangle” hair disorders. Int J Trichol 2011; 3 : 46–56. doi: 10.4103/0974-7753.82124.

7. Rugo S, Lacouture ME, Payne AS. Chemotherapy-induced alopecia. [online]. Available from: https: //www.uptodate.com/contents/chemotherapy-induced-alopecia.

8. Freites-Martinez A, Shapiro J, van den Hurk C et al. CME Part 2: Hair disorders in cancer survivors. J Am Acad Dermatol 2019; 80 (5): 1199–1213. doi: 10.1016/ j.jaad.2018.03.056.

9. Kang D, Kim IR, Choi EK et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 2019; 24 (3): 414–420. doi: 10.1634/theoncologist.2018-0184.

10. Chon SY, Champion RW, Geddes ER et al. Chemotherapy-induced alopecia. J Am Acad Dermatol 2012; 67 (1): 37–47. doi: 10.1016/j.jaad.2011.02.026.

11. Ali SY, Singh G. Radiation-induced alopecia. Int J Trichology 2010; 2 (2): 118–119. doi: 10.4103/0974-7753.77528.

12. Malkinson FD, Keane JT. Radiobiology of the skin: review of some effects on epidermis and hair. J Invest Dermatol 1981; 77 (1): 133–138. doi: 10.1111/1523-1747.ep12479347.

13. Hynková L, Šlampa P, Jančálek R. Radioterapie v léčbě mozkových metastáz. Neurol pro praxi 2016; 17 (5): 293–297.

14. Mahadevan A, Sampson C, LaRosa S et al. Dosimetric analysis of the alopecia reventing effect of hippocampus sparing whole brain radiation therapy. Radiat Oncol 2015; 10 : 245. doi: 10.1186/s13014-015-0555-9.

15. Scoccianti S, Simontacchi G, Talamonti C et al. Scalp-sparing radiotherapy to minimize alopecia in patients with primary brain cancer. The Green Journal. [online]. Available from: www.thegreenjournal.com/article/S0167-8140 (17) 31080-0/pdf.

16. Dueland S, Sauer T, Lund-Johansen F et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003; 42 (4): 345–346. doi: 10.1080/02841860310006038.

17. Zheng H, Zhang H, Zhang T et al. Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: a case report and literature review. Exp Ther Med 2016; 12 (3): 1287–1292. doi: 10.3892/etm.2016.3460.

18. Vokurka S. Mukozitida dutiny ústní a gastrointestinálního traktu u pacientů po chemoterapii –⁠ aktuální přehled. Klin Onkol 2007; 20 (1): 23–28.

19. Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 2017; 163 (2): 199–205. doi: 10.1007/s10549-017-4185-9.

20. Nangia J, Wang T, Osborne C et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 2017; 317 (6): 596–605. doi: 10.1001/jama.2016.20939.

21. Vasconcelos I, Wiesske A, Schoenegg W. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy. Breast 2018; 40 : 1–3. doi: 10.1016/j.breast.2018. 04.012.

22. Friedrichs K, Carstensen MH. Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer –⁠ clinical evaluation of sensor-controlled scalp cooling. Springerplus 2014; 3 : 500. doi: 10.1186/2193-1801-3-500.

23. Rugo HS, Klein P, Melin SA et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017; 317 (6): 606–614. doi: 10.1001/jama.2016.21038.

24. Büchler T. Chlazení hlavy během chemoterapie jako prevence alopecie. Stanovisko České onkologické společnosti. Příloha zápisu ze schůze výboru ČOS ČLS J.E.P. ze dne 26.6.2018. [online]. Dostupné z: https: //www.linkos.cz/ceska-onkologicka-spolecnost-cls-jep/stanoviska-cos/priority-a-stanoviska-cos/chlazeni-hlavy-behen-chemoterapie-jako-prevence-alopecie-stanovisko-ceske-onkolo/.

25. Glaser DA, Hossain P, Perkins W et al. Long-term safety and efficacy of bimatoprost solution 0,03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 2015; 172 (5): 1384–1394. doi: 10.1111/bjd.13443.